Helicobacter pylori vaccines

Patent metadata

Field	Value
Publication number	US-10828358-B2
Application number	US-201616061938-A
Country	US
Kind code	B2
Filing date	Dec 14, 2016
Priority date	Dec 14, 2015
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with Helicobacter pylori , in particular H. pylori infection and gastroduodenal disorders caused by H. pylori . The present invention further relates to methods of detecting H. pylori infection in a subject.

First claim

The invention claimed is:

1. A method of preventing or treating H. pylori infection, the method comprising the step of administering to a subject in need thereof an effective amount of an immunogenic composition comprising at least one isolated (poly-)peptide comprising (i) the amino acid sequence SEQ ID NO: 1 or (ii) an immunogenic fragment of (i), wherein the immunogenic fragment comprises amino acids 34 to 201 of SEQ ID NO: 1, wherein the immunogenic composition further comprises H. pylori gamma-glutamyltranspeptidase (HPG) as addition antigen.

2. The method according to claim 1 , wherein the isolated (poly-)peptide is a recombinant (poly-)peptide.

3. The method according to claim 1 , wherein the immunogenic composition further comprises at least one additional antigen from H. pylori.

4. The method according to claim 3 , wherein the additional antigen is selected from the group consisting of outer membrane proteins and virulence factor proteins of H. pylori and immunogenic fragments thereof.

5. The method according to claim 1 , wherein the isolated (poly-) peptide is a fusion protein.

6. The method according to claim 5 , wherein the fusion protein comprises amino acid sequence of SEQ ID NO: 1 or an immunogenic fragment thereof, wherein the immunogenic fragment comprises amino acids 34 to 201 of SEQ ID NO: 1, and (ii) H. pylori gamma-glutamyltranspeptidase (HPG).

7. The method according to claim 6 , wherein the additional antigen is selected from the group consisting of outer membrane proteins and virulence factor proteins of H. pylori and immunogenic fragments thereof.

8. The method according to claim 1 , wherein the immunogenic composition further comprises at least one different isolated (poly-) peptides comprising (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7; or (ii) an immunogenic variant of (i) comprising an amino acid sequence which is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7; or (iii) an immunogenic fragment of (i) or (ii), wherein the immunogenic fragment comprises at least 6 consecutive amino acids of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

9. The method according to claim 1 , wherein the immunogenic composition further comprises at least one adjuvant.

10. The method according to claim 9 , wherein the at least one adjuvant is selected from the group consisting of toxin-based adjuvants, toll-like receptor (TLR) ligand-based adjuvants, nucleic acid- or vector-based adjuvants, protein-based adjuvants, polymer-based adjuvants, mucosal adjuvants, immune stimulating complex (ISCOM) matrices and combinations of any of the foregoing.

11. The method according to claim 9 , wherein the at least one adjuvant is selected from the group consisting of polycationic polymers or peptides, immunostimulatory deoxynucleotides (ODNs), synthetic KLK peptides, neuroactive compounds, alumn, Freund's complete or incomplete adjuvants, cholera toxin (CT), CTA1-DD, heat-labile enterotoxin (LT), mutants of CT or LT, poly-IC, dendritic cell (DC) binding peptides and C3d fusion proteins.

12. The method according to claim 1 , wherein the immunogenic composition is a pan-protective vaccine.

13. The method according to claim 1 , wherein the H. pylori infection is associated with a gastroduodenal disorder caused by H. pylori.

14. The method of claim 13 , wherein the gastroduodenal disorder is selected from the group consisting of gastritis, chronic gastritis, gastric or duodenal ulcer, stomach cancer and mucosa associated lymphoid tissue (MALT) lymphoma.

15. The method according to claim 1 , wherein the immunogenic composition further comprises one or more pharmaceutically acceptable carriers and/or excipients.

16. The method according to claim 1 , wherein the immunogenic composition induces a humoral and/or cell-mediated immune response that is specific to the polypeptide of SEQ ID NO: 1 in the subject.

17. The method according to claim 13 , wherein the immunogenic composition induces a T-cell response that is specific to the polypeptide of SEQ ID NO: 1 in the subject.

Assignees

• Univ Muenchen Tech
• Max Planck Gesellschaft

Inventors

• Kruse Tobias
• Hornburg Daniel
• Gerhard Markus
• Mann Matthias
• Meissner Felix

Classifications

• A61K39/105 Primary

  Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter · CPC title

• A61K2039/55544

  Bacterial toxins · CPC title

• A61K39/0208 Primary

  Specific bacteria not otherwise provided for · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• G01N33/56922

  Campylobacter · CPC title